Dr. Frances Shepherd CV - (NCRI) is

the elderly: A population-based outcomes study. J Clin Oncol 29: 2011 (supp; abstr
7012).
75. Spigel DR, Harper PA, Hainsworth JD, De Marinis F, Kabbinavar FF, Kim ES, Lynch
TJ, Rosell R, Shepherd FA, Socincki MA. Randomized phase III trial of
gemcitabine/carboplatin with or withour iniparib (BSI-201) in patients with previously
untreated stage IV squamous non-small cell lung cancer (NSCLC). J Clin Oncol 29: 2011
(supp; abstr TPS220).
76. Hilton JF, Seymour L, Le Maitre A, Tu D, Shepherd FA, Bradbury PA. An evaluation of
the possible interaction of gastric acid suppressive medication and the EGFR tyrosine
kinase inhibitor erlotinib. J Clin Oncol 29: 2011 (supp; abstr 7523).
77. Sulpher JA, Owen SP, Hon H, Tobros K, Shepherd FA, et al. Factors influencing a
specific histological diagnosis of non-small cell lung cancer. J Clin Oncol 29: 2011
(supp; abstr 7541).
78. Soulieres D, Wold J, Shepherd FA, et al. Meta-analysis of the predictive and prognostic
value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small
cell lung cancer (NSCLC): Reccomendations of the BioLOGUE advisors. J Clin Oncol
29: 2011 (supp; abstr 7533).
79. Pintille M, Sykes J, Jurisica I, Shepherd FA, Tsao MS. Comparison of different
strategies for finding clinically useful signatures. Proc 32 nd Annual Conference of the
International Society for Clinical Biostatistics. Ottawa. 21-25 August 2011. P. 119
80. Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ. Adoption of
adjuvant chemotherapy for non-small cell lung cancer: a population-based outcomes study.
Presented at ASCO, Chicago, Il, June 2011.
81. Cuffe S, Graziano S, Abderrahmane B, Pignon JP on behalf of the LACE BIO Group,
Ezzalfani M, Seymour, L, Strevel E, Burkes R, Capelletti M, Janne P, Tsao MS,
Shepherd FA. A pooled exploratory anaylysis of the impact of tumour size and KRAS
mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in
node negative (NO) non-small cell lung cancer. Presented at the IASLC 14 th World
Conference on Lung Cancer, Amsterdam June 2011. J Thorac Oncol 2011; 6: S5462-63
82. Cuffe S, Booth C, Peng Y, Darling G, Li G, Kong W, Mackillop WJ, Shepherd FA.
Uptake of adjuvant chemotherapy, its tolerability and impact on survival among elderly
non-small cell lung cancer patients in Ontario: a population-based outcomes study.
Presented at the IASLC 14 th World Conference on Lung Cancer, Amsterdam June 2011.
J Thorac Oncol 2011; 6: S5463-64
83. Mauguen A, Michiels S, Burdett S, Tierney JF, Sause W, Mandrekar SJ, Dahlberg SE,
Shepherd FA, PArmar M, Perry MC, O’Brien M, Le Pechoux C, Pignon J-P, On behalf
of the Surrogate Project Collaborative Group. Evaluation of progression-free survival as a
suurogate endpoint for overall survival when evaluating the effect of chemotherapy and
radiotherapy in locally advanced lung cancer using data from four individual patient data
meta-analyses. Presented at the IASLC 14 th World Conference on Lung Cancer,
Amsterdam June 2011. J Thorac Oncol 2011; 6: S5464-65.
84. Novello S, Ramlau R, Gorbunova VA, Ciuleanu TE, Ozguroglu M, Goksel T, Baldotto
C, Bennoune J, Shepherd FA, Scagliotti G. Alfibercept in combination with docetaxel
for second-line treatment of locally advanced or metastatic non-small cell lung cancer
(NSCLC): Final results of multinational placebo-controlled phase III trial (EFC10261-
VITAL). Presented at the IASLC 14 th World Conference on Lung Cancer, Amsterdam
June 2011. J Thorac Oncol 2011; 6: S570.
85. Yanagawa N, Saieg MA, Kohler D, Sykes J, John T, Santod GDC, Pintile M, Shepherd
FA, Tsao MS. Apmlification of MYC abd aberrant expression of P53 and PTEN are
predictive of ability to form primary tumor zenografts in resected non-small cell lung
23